Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

SPECT/CT imaging

  • Efficacy of [<sup>67</sup>Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2–Positive Neuroendocrine Tumors
    You have access
    Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2–Positive Neuroendocrine Tumors
    Fabrice Ngoh Njotu, Jessica Pougoue Ketchemen, Anjong Florence Tikum, Hanan Babeker, Brian D. Gray, Koon Y. Pak, Maruti Uppalapati and Humphrey Fonge
    Journal of Nuclear Medicine April 1, 2024, 65 (4) 533-539; DOI: https://doi.org/10.2967/jnumed.123.265997
  • First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
    You have access
    First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
    Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376
  • You have access
    Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti–Fibroblast Activation Protein Antibody
    Tessa van der Geest, Peter Laverman, Danny Gerrits, Birgitte Walgreen, Monique M. Helsen, Christian Klein, Tapan K. Nayak, Gert Storm, Josbert M. Metselaar, Marije I. Koenders and Otto C. Boerman
    Journal of Nuclear Medicine January 1, 2017, 58 (1) 151-155; DOI: https://doi.org/10.2967/jnumed.116.177931
  • You have access
    Imaging VCAM-1 as an Indicator of Treatment Efficacy in Metastatic Ovarian Cancer
    Jennifer M. Scalici, Stephanie Thomas, Christine Harrer, Timothy A. Raines, Joanna Curran, Kristen A. Atkins, Mark R. Conaway, Linda Duska, Kimberly A. Kelly and Jill K. Slack-Davis
    Journal of Nuclear Medicine November 1, 2013, 54 (11) 1883-1889; DOI: https://doi.org/10.2967/jnumed.112.117796
SNMMI

© 2025 SNMMI

Powered by HighWire